Dermatology

Atopic Dermatitis

Questions discussed in this category

With the approval of oral JAK inhibitors such as Upadacitinib for atopic dermatitis, how are you considering its safety profile in comparison to traditional immunosuppressants such as prednisone, methotrexate, azathioprine, and mycophenolate?

Especially in the setting of these being more narrow acting than tofacitinib, should we consider them safer than our old drugs?

2 Answers available

What is your approach to treating patients with dupilumab induced facial redness?

2 Answers available

Related Topics in Dermatology